Coherus BioSciences (NASDAQ:CHRS – Get Rating) had its target price lowered by Barclays from $13.00 to $8.00 in a research note issued to investors on Tuesday, The Fly reports. A number of other equities research analysts have also issued reports on CHRS. StockNews.com started coverage on Coherus BioSciences in a research note on Thursday, May […]
Riding the Ozempic Wave | Law Street Media lawstreetmedia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lawstreetmedia.com Daily Mail and Mail on Sunday newspapers.
Coherus BioSciences, Inc. (NASDAQ:CHRS – Get Rating) was the recipient of a large increase in short interest in the month of March. As of March 15th, there was short interest totalling 12,050,000 shares, an increase of 22.5% from the February 28th total of 9,840,000 shares. Based on an average daily trading volume, of 1,260,000 shares, […]
UBS Group upgraded shares of Coherus BioSciences (NASDAQ:CHRS – Get Rating) from a neutral rating to a buy rating in a report published on Tuesday morning, MarketBeat.com reports. The firm currently has $11.00 price objective on the biotechnology company’s stock. Several other equities research analysts have also commented on CHRS. HC Wainwright cut their price […]
Femasys (NASDAQ:FEMY – Get Rating) had its target price reduced by stock analysts at Chardan Capital from $12.00 to $10.00 in a research report issued on Thursday, The Fly reports. Femasys Price Performance Shares of NASDAQ:FEMY traded down $0.05 during trading on Thursday, reaching $1.15. The company had a trading volume of 2,446 shares, compared […]